Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Quantum-Si ( (QSI) ) has shared an announcement.
On May 15, 2026, Quantum-Si held its Annual Meeting, with approximately 84.59% of the total voting power of its Class A and Class B common stock represented, establishing a quorum. Shareholders reelected all listed director nominees to serve until the 2027 annual meeting, including founder Jonathan M. Rothberg, Ph.D., reflecting continued support for the company’s existing leadership.
At the same meeting, shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026. Investors also approved on an advisory basis the compensation of the company’s named executive officers, signaling broad backing for current governance, financial oversight, and executive pay structures.
The most recent analyst rating on (QSI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.
Spark’s Take on QSI Stock
According to Spark, TipRanks’ AI Analyst, QSI is a Neutral.
The score is held back primarily by weak financial performance (minimal/declining revenue, large ongoing losses, and sustained cash burn). The latest earnings call adds support via a strong cash runway and tangible Proteus technology milestones, but near-term commercialization remains uncertain. Technicals are neutral-to-weak with the stock still well below long-term moving averages, and valuation offers limited support due to negative earnings and no dividend.
To see Spark’s full report on QSI stock, click here.
More about Quantum-Si
Quantum-Si operates in the life sciences and biotechnology tools industry, focusing on next-generation protein sequencing technologies and related analytical platforms for research and clinical applications. The company targets scientists and healthcare stakeholders seeking higher-resolution proteomic data to advance drug discovery, diagnostics, and precision medicine in a competitive and rapidly evolving market.
Average Trading Volume: 4,562,464
Technical Sentiment Signal: Strong Sell
Current Market Cap: $201.9M
For a thorough assessment of QSI stock, go to TipRanks’ Stock Analysis page.